InnovAge Names Christine Bent as Chief Operations Officer 2-03-2023, 04:42

Gregory Basil MD to Join Aclarion as a Key Opinion Leader 31-01-2023, 22:04

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00